324 related articles for article (PubMed ID: 14975529)
1. Shigella flexneri infection: pathogenesis and vaccine development.
Jennison AV; Verma NK
FEMS Microbiol Rev; 2004 Feb; 28(1):43-58. PubMed ID: 14975529
[TBL] [Abstract][Full Text] [Related]
2. Live attenuated Shigella flexneri mutants as vaccine candidates against shigellosis and vectors for antigen delivery.
Phalipon A; Sansonetti P
Biologicals; 1995 Jun; 23(2):125-34. PubMed ID: 7546655
[TBL] [Abstract][Full Text] [Related]
3. Outer Membrane Vesicles Derived from
Tian H; Li B; Xu T; Yu H; Chen J; Yu H; Li S; Zeng L; Huang X; Liu Q
Appl Environ Microbiol; 2021 Sep; 87(19):e0096821. PubMed ID: 34319809
[TBL] [Abstract][Full Text] [Related]
4. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602.
Coster TS; Hoge CW; VanDeVerg LL; Hartman AB; Oaks EV; Venkatesan MM; Cohen D; Robin G; Fontaine-Thompson A; Sansonetti PJ; Hale TL
Infect Immun; 1999 Jul; 67(7):3437-43. PubMed ID: 10377124
[TBL] [Abstract][Full Text] [Related]
5. The pathogenesis of Shigella flexneri infection: lessons from in vitro and in vivo studies.
Philpott DJ; Edgeworth JD; Sansonetti PJ
Philos Trans R Soc Lond B Biol Sci; 2000 May; 355(1397):575-86. PubMed ID: 10874731
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a multicomponent live, attenuated Shigella flexneri vaccine.
DeLaine BC; Wu T; Grassel CL; Shimanovich A; Pasetti MF; Levine MM; Barry EM
Pathog Dis; 2016 Jul; 74(5):. PubMed ID: 27106253
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of shigellosis: from molecular and cellular biology of epithelial cell invasion to tissue inflammation and vaccine development.
Sansonetti PJ
Jpn J Med Sci Biol; 1998; 51 Suppl():S69-80. PubMed ID: 10211438
[No Abstract] [Full Text] [Related]
8. Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice.
Farzam N; Ramon-Saraf R; Banet-Levi Y; Lerner-Geva L; Ashkenazi S; Kubler-Kielb J; Vinogradov E; Robbins JB; Schneerson R
Vaccine; 2017 Sep; 35(37):4990-4996. PubMed ID: 28797729
[TBL] [Abstract][Full Text] [Related]
9. Construction and evaluation of a double mutant of Shigella flexneri as a candidate for oral vaccination against shigellosis.
Sansonetti PJ; Arondel J
Vaccine; 1989 Oct; 7(5):443-50. PubMed ID: 2683460
[TBL] [Abstract][Full Text] [Related]
10. Construction of a multivalent vaccine strain of Shigella flexneri and evaluation of serotype-specific immunity.
Jennison AV; Roberts F; Verma NK
FEMS Immunol Med Microbiol; 2006 Apr; 46(3):444-51. PubMed ID: 16553820
[TBL] [Abstract][Full Text] [Related]
11. New animal model of shigellosis in the Guinea pig: its usefulness for protective efficacy studies.
Shim DH; Suzuki T; Chang SY; Park SM; Sansonetti PJ; Sasakawa C; Kweon MN
J Immunol; 2007 Feb; 178(4):2476-82. PubMed ID: 17277155
[TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D
Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247
[TBL] [Abstract][Full Text] [Related]
13. Secretory IgA-mediated neutralization of Shigella flexneri prevents intestinal tissue destruction by down-regulating inflammatory circuits.
Boullier S; Tanguy M; Kadaoui KA; Caubet C; Sansonetti P; Corthésy B; Phalipon A
J Immunol; 2009 Nov; 183(9):5879-85. PubMed ID: 19828639
[TBL] [Abstract][Full Text] [Related]
14. Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection.
DuPont HL; Hornick RB; Snyder MJ; Libonati JP; Formal SB; Gangarosa EJ
J Infect Dis; 1972 Jan; 125(1):12-6. PubMed ID: 4550416
[No Abstract] [Full Text] [Related]
15. Towards a non-living vaccine against Shigella flexneri: from the inactivation procedure to protection studies.
Camacho AI; Souza-Rebouças J; Irache JM; Gamazo C
Methods; 2013 May; 60(3):264-8. PubMed ID: 23046911
[TBL] [Abstract][Full Text] [Related]
16. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies.
Kotloff KL; Winickoff JP; Ivanoff B; Clemens JD; Swerdlow DL; Sansonetti PJ; Adak GK; Levine MM
Bull World Health Organ; 1999; 77(8):651-66. PubMed ID: 10516787
[TBL] [Abstract][Full Text] [Related]
17. Development of an auxotrophic oral live Shigella flexneri vaccine.
Lindberg AA; Kärnell A; Stocker BA; Katakura S; Sweiha H; Reinholt FP
Vaccine; 1988 Apr; 6(2):146-50. PubMed ID: 2838986
[TBL] [Abstract][Full Text] [Related]
18. Shigellosis: the current status of vaccine development.
Kweon MN
Curr Opin Infect Dis; 2008 Jun; 21(3):313-8. PubMed ID: 18448978
[TBL] [Abstract][Full Text] [Related]
19. Shigellosis.
Niyogi SK
J Microbiol; 2005 Apr; 43(2):133-43. PubMed ID: 15880088
[TBL] [Abstract][Full Text] [Related]
20. Vaccine strain Sh. flexneri T32-Istrati. Studies in animals and in volunteers. Antidysentery immunoprophylaxis and immunotherapy by live vaccine Vadizen (Sh. flexneri T32-Istrati).
Meitert T; Pencu E; Ciudin L; Tonciu M
Arch Roum Pathol Exp Microbiol; 1984; 43(3-4):251-78. PubMed ID: 6400299
[No Abstract] [Full Text] [Related]
[Next] [New Search]
